Upsher-Smith Laboratories, LLC declared that it sought U.S Food and Drug Administration‘s approval for new drug application (ANDA) for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg, a generic version of the brand product, Bumex Tablets.
Rusty Field, President and CEO of Upsher-Smith said “We were part of one of the largest pharmaceutical transactions of the year and continued to expand our generic product portfolio. We are pleased to begin this year by adding Bumetanide Tablets to our portfolio of quality generic products.”
Upsher-Smith will be prepared to begin shipping product to wholesalers in early February 2018. According to IMS Health, The bumetanide tablet market had U.S. sales of approximately $84.5 million for the 12 months ending November, 2017.
Image Source: Upsher-Smith Laboratories